A study presented at ENDO 2025 by Dr. Shellsea Portillo Canales (SSM Health, St. Louis University Hospital) found that widely used GLP‑1 receptor agonists—semaglutide, dulaglutide, and tirzepatide—were associated with significant improvements in testosterone among obese men, many of whom also had type 2 diabetes. After 18 months, the share